Congressman Greg Murphy, M.D., alongside Congressmen Adam Gray (D-CA) and Neal Dunn (R-FL), introduced the Protecting Patient Access to Cancer and Complex Therapies Act, legislation to revert physician reimbursement for administering drugs under Medicare Part B to Average Sales Price (ASP) plus 6 percent, create an additional rebate paid by manufacturers, and hold patients harmless by basing coinsurance rates off the Maximum Fair Price (MFP).

Rural hospitals across the U.S. say they’re being forced to consider tough choices — like cutting services for children or cancer patients — after President Donald Trump signed into law a sprawling domestic policy bill that includes sweeping cuts to not only Medicaid but the Affordable Care Act, as well.

The Community Oncology Alliance (COA) strongly supports the reintroduction of the Protecting Patient Access to Cancer and Complex Therapies Act in the United States House of Representatives.

Kelli Reardon undergoes an MRI twice a year to screen for breast cancer, a measure she said she must take to protect her health.

Chemotherapy doesn’t just attack cancer cells; it often takes the nervous system along for the ride.

Administrative delays and insurance red tape experienced by patients with advanced cancer can lead to feelings of fear and mistrust in a healthcare system which they believed would protect them in their most vulnerable state, Dr. Alexandra Zaleta said in an interview with CURE.

As a cancer patient, access to innovative drugs can help extend your life — that is if you have health insurance, a new study finds.

New clinical trials are opening or progressing in several hard-to-treat cancers, including pediatric brain tumors, colorectal cancer, ovarian cancer, bladder cancer and leukemia.

Prehabilitation and baseline physiological assessments before breast cancer surgery and treatment may enhance resilience to side effects, improve recovery and identify patients at an increased risk for developing lymphedema — a chronic and often debilitating condition that causes swelling in the affected arm and can arise weeks, months or even years after cancer intervention.

One of the most challenging aspects of conducting cancer clinical trials has always been the exclusion criteria, explains David Gerber, MD, a medical oncologist at UT Southwestern Medical Center in Dallas.